Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor

被引:47
作者
Gueller, Ulrich [1 ,2 ]
Tarantino, Ignazio [3 ]
Cerny, Thomas [1 ]
Schmied, Bruno M. [4 ]
Warschkow, Rene [4 ,5 ]
机构
[1] Kantonsspital St Gallen, Div Med Oncol & Hematol, CH-9007 St Gallen, Switzerland
[2] Univ Hosp Berne, Univ Clin Visceral Surg & Med, CH-3010 Bern, Switzerland
[3] Heidelberg Univ, Dept Gen Abdominal & Transplant Surg, D-69120 Heidelberg, Germany
[4] Kantonsspital St Gallen, Dept Surg, CH-9007 St Gallen, Switzerland
[5] Heidelberg Univ, Inst Med Biometry & Informat, D-69120 Heidelberg, Germany
关键词
Gastrointestinal stromal tumors (GIST); Surveillance; Epidemiology and End Results (SEER) database; Trend analysis; Gastric GIST; ADJUVANT IMATINIB; RANDOMIZED-TRIAL; TYROSINE KINASE; EPIDEMIOLOGY; MESYLATE; SPAIN; GIST;
D O I
10.1186/s12885-015-1554-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The objective of the present population-based analysis was to assess survival patterns in patients with resected and metastatic GIST. Methods: Patients with histologically proven GIST were extracted from the Surveillance, Epidemiology and End Results (SEER) database from 1998 through 2011. Survival was determined applying Kaplan-Meier-estimates and multivariable Cox-regression analyses. The impact of size and mitotic count on survival was assessed with a generalized receiver-operating characteristic-analysis. Results: Overall, 5138 patients were included. Median age was 62 years (range: 18-101 years), 47.3 % were female, 68.8 % Caucasians. GIST location was in the stomach in 58.7 % and small bowel in 31.2 %. Lymph node and distant metastases were found in 5.1 and 18.0 %, respectively. For non-metastatic GIST, three-year overall survival increased from 68.5 % (95 % CI: 58.8-79.8 %) in 1998 to 88.6 % (95 % CI: 85.3-92.0 %) in 2008, cancer-specific survival from 75.3 % (95 % CI: 66.1-85.9 %) in 1998 to 92.2 % (95 % CI: 89.4-95.1 %) in 2008. For metastatic GIST, three-year overall survival increased from 15.0 % (95 % CI: 5.3-42.6 %) in 1998 to 54.7 % (95 % CI: 44.4-67.3 %) in 2008, cancer-specific survival from 15.0 % (95 % CI: 5.3-42.6 %) in 1998 to 61.9 % (95 % CI: 51.4-74.5 %) in 2008 (all P-Trend < 0.05). Conclusions: This is the first SEER trend analysis assessing outcomes in a large cohort of GIST patients over a 11-year time period. The analysis provides compelling evidence of a statistically significant and clinically relevant increase in overall and cancer-specific survival from 1998 to 2008, both for resected as well as metastatic GIST.
引用
收藏
页数:11
相关论文
共 24 条
[21]  
Tran T, 2005, AM J GASTROENTEROL, V100, P162, DOI [10.1111/j.1572-0241.2005.40709.x, 10.1111/j.1572-0241.2005.41007.x]
[22]   Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial [J].
Verweij, J ;
Casali, PG ;
Zalcberg, J ;
LeCesne, A ;
Reichardt, P ;
Blay, JY ;
Issels, R ;
van Oosterom, A ;
Hogendoorn, PCW ;
Van Glabbeke, M ;
Bertulli, R ;
Judson, I .
LANCET, 2004, 364 (9440) :1127-1134
[23]   Building the infrastructure for nationwide cancer surveillance and control - a comparison between The National Program of Cancer Registries (NPCR) and The Surveillance, Epidemiology, and End Results (SEER) Program (United States) [J].
Wingo, PA ;
Jamison, PM ;
Hiatt, RA ;
Weir, HK ;
Gargiullo, PM ;
Hutton, M ;
Lee, NC ;
Hall, HI .
CANCER CAUSES & CONTROL, 2003, 14 (02) :175-193
[24]   An Evaluation of 2537 Gastrointestinal Stromal Tumors for a Proposed Clinical Staging System [J].
Woodall, Charles E., III ;
Brock, Guy N. ;
Fan, Jie ;
Byam, Jerome A. ;
Scoggins, Charles R. ;
McMasters, Kelly M. ;
Martin, Robert C. G., II .
ARCHIVES OF SURGERY, 2009, 144 (07) :670-678